Fabry disease (FD), also known as Anderson-Fabry disease, is an X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (α-Gal A)[1]. This enzyme is responsible for cleaving the terminal galactose from globotriaosylceramide (Gb3) and related glycosphingolipids. The deficiency leads to progressive accumulation of these lipids throughout the body, including in the kidneys, heart, nervous system, and skin[2].
The disease affects approximately 1 in 40,000 to 1 in 120,000 males, with female carriers showing variable clinical manifestations due to X-chromosome inactivation. The accumulation of Gb3 and its deacylated form, lyso-Gb3, initiates a cascade of cellular dysfunction that ultimately leads to neurodegeneration, renal failure, cardiac disease, and premature death[3].
The GLA gene on chromosome Xq22 encodes alpha-galactosidase A, a 429-amino-acid glycoprotein enzyme that functions as a homodimer[4]. The enzyme is synthesized in the endoplasmic reticulum, processed through the Golgi apparatus, and targeted to lysosomes via mannose-6-phosphate receptor-mediated trafficking.
Over 900 disease-causing mutations have been identified in the GLA gene, including missense, nonsense, splice site, and deletion mutations. The genotype largely determines the phenotype:
Globotriaosylceramide (Gb3, also called ceramide trihexoside) is a neutral glycosphingolipid found in cell membranes throughout the body[5]. In Fabry disease, the inability to catabolize Gb3 leads to its accumulation in:
The accumulation pattern explains the multi-system nature of the disease and the progressive involvement of different organs.
Lyso-Gb3 (globotriaosylsphingosine) is the deacylated form of Gb3 and serves as a sensitive biomarker for disease activity[6]. Unlike Gb3, lyso-Gb3 is soluble and can be measured in plasma. It is not only a marker but also contributes to pathogenesis:
The accumulation of Gb3 in endothelial cells represents one of the earliest and most significant pathological changes[7]. Endothelial dysfunction manifests as:
These changes lead to reduced cerebral blood flow, increased risk of stroke, and widespread microvascular dysfunction. The cerebral vasculature shows particular vulnerability, with studies demonstrating reduced cerebral perfusion in Fabry patients even before clinical symptoms appear[8].
Cardiac disease is a major cause of morbidity and mortality in Fabry disease[9]. The accumulation of Gb3 in cardiac myocytes leads to:
Cardiac magnetic resonance imaging (MRI) shows characteristic patterns of late gadolinium enhancement in the basal inferolateral wall, which correlates with myocardial fibrosis[10].
Renal involvement is a hallmark of classical Fabry disease, with progressive proteinuria and eventual renal failure[11]. The pathogenesis involves:
Without treatment, most male patients develop end-stage renal disease by the fourth or fifth decade of life.
Small fiber neuropathy is an early and debilitating manifestation[12]. Patients experience:
The pathogenesis involves accumulation of Gb3 in dorsal root ganglion neurons and autonomic neurons, leading to axonal degeneration.
Cerebral involvement includes[13]:
The risk of stroke in Fabry patients is elevated even in heterozygous females, reflecting the systemic nature of the vascular pathology.
Recent research has identified an association between GLA mutations and Parkinson's disease (PD)[14]. While the mechanism is not fully understood, several lines of evidence suggest a link:
The exact relationship remains an area of active investigation, with studies examining whether Fabry disease patients have increased PD risk and whether GLA variants modify PD progression.
Beyond Parkinson's disease, Fabry pathology intersects with other neurodegenerative conditions[15]:
The lysosomal storage in Fabry disease shares features with other lysosomal disorders that are increasingly recognized as risk factors for neurodegeneration.
Enzyme replacement therapy (ERT) is the standard treatment for Fabry disease[16]:
ERT reduces Gb3 accumulation in various tissues and slows disease progression, but its efficacy depends on early initiation before irreversible organ damage occurs. Limitations include:
Migalastat (Galafold) is a pharmacological chaperone that binds to and stabilizes mutant α-Gal A, promoting proper folding and trafficking to lysosomes[17]. It is indicated for patients with amenable GLA mutations (approximately 35-50% of patients).
Advantages over ERT include oral administration and potential for better tissue distribution. However, only patients with specific mutations respond, limiting its applicability.
Gene therapy approaches are under investigation[18]:
Early-phase clinical trials have shown promise, with sustained α-Gal A activity in some patients.
Management of specific complications includes[19]:
The Fabry disease pathway intersects with several neurodegenerative disease mechanisms:
Multiple clinical trials are investigating new therapies, including gene therapy (AT-GAA), next-generation ERT, and combination approaches[20].
Fabry disease is a systemic lysosomal storage disorder that provides important insights into the relationship between glycosphingolipid metabolism and neurodegeneration. The disease mechanism involves accumulation of Gb3 and lyso-Gb3, leading to endothelial dysfunction, organ failure, and central nervous system pathology. Treatment options have expanded significantly with enzyme replacement therapy, pharmacological chaperones, and emerging gene therapies. The association between Fabry disease and Parkinson's disease highlights the importance of lysosomal function in neurodegenerative processes.
Fabry disease exhibits an X-linked recessive inheritance pattern, affecting predominantly males with an estimated prevalence of approximately 1 in 40,000 to 1 in 120,000 births[1:1]. However, this figure may underestimate the true prevalence due to underdiagnosis and the existence of milder variants that present later in life. Newborn screening studies using enzyme activity assays have identified higher than expected prevalence, particularly for the posterior variant form, suggesting that Fabry disease may be more common than traditionally recognized[2:1].
The distribution of GLA mutations shows geographic variation, with certain mutations appearing more frequently in specific populations. For example, the p.N215S mutation is particularly common in individuals of European descent and is associated with a later-onset cardiac phenotype. Founder mutations have been identified in various populations, including the Appalachian region of the United States and certain regions of Portugal and Spain[3:1].
Heterozygous females (carriers) show variable clinical manifestations due to random X-chromosome inactivation (lyonization). While many carriers are asymptomatic, approximately 70-80% develop symptoms during their lifetime. The variability in female carriers reflects the pattern of X-inactivation in different tissues and the proportion of cells expressing the mutant versus wild-type GLA allele[4:1].
Common manifestations in female carriers include:
Importantly, female carriers can transmit the disease to all their sons and daughters, making family screening essential following diagnosis.
The clinical phenotype in Fabry disease correlates strongly with the specific GLA mutation and residual enzyme activity[5:1]. Several classification systems have been proposed:
Classical phenotype (classic Fabry): Associated with mutations resulting in <1% residual α-Gal A activity. These include many nonsense mutations, frameshift mutations, and certain missense mutations that completely destabilize the enzyme. Patients present in childhood with characteristic features including neuropathic pain, angiokeratomas, hypohidrosis, and corneal opacities.
Later-onset phenotype (variant Fabry): Associated with mutations allowing 1-30% residual enzyme activity. These patients typically present in adulthood with predominant cardiac or renal involvement, with fewer or absent classic skin and neurological manifestations. The p.N215S mutation is the most common cause of the later-onset phenotype.
Intermediate phenotypes: Some mutations produce intermediate enzyme activity and variable presentations. These may include patients with atypical presentations or combinations of classic and later-onset features.
The diagnosis of Fabry disease should be considered in patients presenting with characteristic signs and symptoms
Childhood presentations:
Adult presentations:
Enzyme activity testing: The gold standard for diagnosis in males is measurement of α-Gal A activity in plasma, leukocytes, or dried blood spots. Activity below 1 nmol/hr/mg (approximately <10% of normal) confirms the diagnosis. In females, enzyme activity can be normal due to X-chromosome inactivation, making genetic testing necessary[7:1].
Genetic testing: DNA sequencing of the GLA gene identifies disease-causing mutations. This is essential for:
Biomarker testing: Plasma lyso-Gb3 levels are markedly elevated in classical Fabry disease and provide a sensitive biomarker for disease activity and treatment response. Levels are typically lower in variant forms[8:1].
Histopathology: Tissue biopsy (skin, kidney, heart) may show characteristic myelin-like inclusions (zebra bodies) on electron microscopy, though this is rarely needed for diagnosis.
Newborn screening for Fabry disease using enzyme activity assays has been implemented in several regions, including parts of the United States, Europe, and Japan[9:1]. The goal is to identify affected individuals before the onset of irreversible organ damage, enabling early intervention with enzyme replacement therapy or other treatments.
Screening has revealed a higher than expected prevalence, particularly for the later-onset variant. However, the implementation of newborn screening raises complex issues regarding:
Optimal management of Fabry disease requires a multidisciplinary team including- Metabolic geneticist: Coordinates overall care and initiates specific therapies
Regular monitoring is essential to detect disease progression and treatment response
Renal monitoring: Quarterly urine protein/creatinine ratio, serum creatinine with eGFR calculation. More frequent monitoring with progressive disease.
Neurological assessment: Annual neurological examination, pain assessment scales, and autonomic function testing as indicated.
Ophthalmological examination: Annual slit-lamp examination for corneal involvement.
Quality of life assessment: Validated questionnaires for pain, depression, anxiety, and functional status.
Pregnancy in Fabry disease requires specialized management- Assessment of renal and cardiac function before conception
Research continues to identify and validate biomarkers for Fabry disease:
Beyond current therapies, several approaches are being investigated:
The study of Fabry disease provides important insights into:
Research in Fabry disease may therefore inform therapeutic approaches for more common neurodegenerative conditions.
Fabry disease represents a paradigm for understanding lysosomal storage disorders and their relationship to neurodegeneration. The identification of GLA mutations and the subsequent accumulation of Gb3 and lyso-Gb3 provides a clear mechanistic link between metabolic dysfunction and neuronal pathology. Understanding this relationship offers insights into broader neurodegenerative processes and potential therapeutic strategies.
Desnick, R. J., et al. (2003). Fabry disease: An inherited multisystem disease'. Journal of Inherited Metabolic Disease. 2003. ↩︎ ↩︎
Germain, D. P. (2010). Fabry disease. Orphanet Journal of Rare Diseases. 2010. ↩︎ ↩︎
Aerts, J. M., et al. (2010). Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proceedings of the National Academy of Sciences. 2010. ↩︎ ↩︎
Bishop, D. F., et al. (1988). Human alpha-galactosidase A: Nucleotide sequence of a cDNA clone encoding the mature enzyme'. Proceedings of the National Academy of Sciences. 1988. ↩︎ ↩︎
Moore, D. F., et al. (2001). The renin-angiotensin system in Fabry disease. Kidney International. 2001. ↩︎ ↩︎
van der Linde, C. C., et al. (2017). Lyso-Gb3: An informative biomarker in Fabry disease'. Clinical Therapeutics. 2017. ↩︎
Rombach, S. M., et al. (2014). Vascular aspects of Fabry disease in relation to clinical manifestations. Journal of Inherited Metabolic Disease. 2014. ↩︎ ↩︎
Buechner, S., et al. (2008). Central nervous system involvement in Anderson-Fabry disease: A clinical and MRI remission study'. Journal of Neurology, Neurosurgery & Psychiatry. 2008. ↩︎ ↩︎
Linhart, A., et al. (2000). Cardiac involvement in Fabry disease. Acta Paediatrica. 2000. ↩︎ ↩︎
Moon, J. C., et al. (2003). Cardiovascular magnetic resonance with delayed enhancement in Fabry disease. Journal of Cardiovascular Magnetic Resonance. 2003. ↩︎
Tondel, C., et al. (2011). Renal pathology in Fabry disease. Journal of Inherited Metabolic Disease. 2011. ↩︎
Torras, J., et al. (2019). Peripheral neuropathy in Fabry disease: Pathogenesis and current therapies'. Neurological Sciences. 2019. ↩︎
Jardim, C., et al. (2020). Central nervous system involvement in Fabry disease. Current Treatment Options in Neurology. 2020. ↩︎
Wise, A. H., et al. (2018). The role of lysosomal enzymes in Parkinson's disease. Movement Disorders. 2018. ↩︎
van der Linde, S., et al. (2017). Fabry disease and neurodegeneration: An overview'. Molecular Genetics and Metabolism. 2017. ↩︎
Eng, C. M., et al. (2001). A phase 3, randomized, double-blind, placebo-controlled study of agalsidase alfa enzyme replacement therapy in Fabry disease. Molecular Genetics and Metabolism. 2001. ↩︎
Germain, D. P., et al. (2016). Migalastat in patients with Fabry disease: The ATTRACT study'. Journal of Medical Genetics. 2016. ↩︎
Khan, A., et al. (2020). Gene therapy for Fabry disease: A review of current approaches'. Journal of Clinical Medicine. 2020. ↩︎
Mehta, A., et al. (2009). Fabry disease: A review of current management strategies'. International Journal of Clinical Pharmacy. 2009. ↩︎
Thomas, S., et al. (2020). Clinical trials in Fabry disease: Current status and future directions'. Molecular Genetics and Metabolism. 2020. ↩︎